June 27th, 2022
May 6th, 2022
October 4th, 2021
September 22nd, 2021
May 17,th 2021
On May 17th, 2021, HRSA sent six pharmaceutical manufacturers letters stating that their restriction of 340B pricing to Contract Pharmacies is in direct violation of 340B statute.
January 3rd, 2022
January 1st, 2021
June 1st, 2022
*Calquence and Lynparza voluntary contracts restored effective October 1st, 2022
Effective August 1st, 2022, Bausch Health will only provide 340B priced product to a single Contract Pharmacy if Covered Entity doesn’t have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP.
September 1st, 2022
Boehringer Ingelheim announced effective September 1st, 2022, an expansion to their contract pharmacy policy to include grantees enrolled in the Consolidated Health Center Program (CH/CHC). All other Federal Grantees not subject to limitations.
December 1st, 2021
Effective December 1st, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions from August 1st, 2021, remain effective. Link to both notices below.
Bristol Myers Squibb
*Camzyos effective July 1st, 2022
At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.
December 10th, 2021
July 1st, 2022
Effective July 1st, 2022, GSK will no longer offer voluntary 340B pricing on two orphan drugs (NUCALA and ZEJULA) to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact Covered Entities not subject to the orphan drug exclusion.
April 1st, 2022
May 2nd, 2022
January 1st, 2022
May 31st, 2022
September 1st, 2021
Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.
January 24th, 2022
January, 1st 2021
Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.